(CercleFinance.com) – ViiV Healthcare, a global HIV company majority-owned by GlaxoSmithKline (GSK), presented data on Saturday March 6 from a phase IIIb study evaluating the long-acting cabotegravir and rilpivirine regimen for HIV treatment.
The week 96 results show the effectiveness of both monthly treatment and every 2 months administration over the long term in patients with undetectable HIV burden.
‘This regimen may allow people living with HIV to reduce the number of days of treatment from 365 to 12 or 6 days per year, which represents a paradigm shift in their experience of treating HIV,’ says Hans Jäeger, MD. , former medical director of MVZ Karlsplatz, center for clinical HIV research and care, Munich
Copyright (c) 2021 CercleFinance.com. All rights reserved.
–
